313 related articles for article (PubMed ID: 37558542)
41. C-reactive protein as a prognostic predictor for non-muscle invasive bladder cancer after intravesical bacillus Calmette-Guérin therapy: A Japan Urological Oncology Group study analysis.
Nishikawa R; Miyake M; Morizane S; Shimizu R; Teraoka S; Honda M; Iida K; Nishimura N; Sazuka T; Kimura T; Ito A; Shiga K; Taoka R; Kojima T; Kobayashi T; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K; Takenaka A
Int J Urol; 2023 Mar; 30(3):299-307. PubMed ID: 36448522
[TBL] [Abstract][Full Text] [Related]
42. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
[TBL] [Abstract][Full Text] [Related]
43. Patient Preferences for Treatment of Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: A Cross-country Choice Experiment.
Collacott H; Krucien N; Heidenreich S; Catto JWF; Ghatnekar O
Eur Urol Open Sci; 2023 Mar; 49():92-99. PubMed ID: 36874596
[TBL] [Abstract][Full Text] [Related]
44. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer.
Roumiguié M; Kamat AM; Bivalacqua TJ; Lerner SP; Kassouf W; Böhle A; Brausi M; Buckley R; Persad R; Colombel M; Lamm D; Palou-Redorta J; Soloway M; Brothers K; Steinberg G; Lotan Y; Sylvester R; Alfred Witjes J; Black PC
Eur Urol; 2022 Jul; 82(1):34-46. PubMed ID: 34955291
[TBL] [Abstract][Full Text] [Related]
45. Comparison of Bacillus Calmette-Guérin Maintenance Therapy with Monthly Instillations and the Southwest Oncology Group Protocol in the Treatment of Non-muscle-invasive Bladder Cancer.
Nurminen P; Nummi A; Kesti O; Ettala O; Högerman M; Järvinen R; Sairanen J; Kaipia A; Boström PJ
Eur Urol Focus; 2023 Nov; 9(6):1000-1007. PubMed ID: 37169643
[TBL] [Abstract][Full Text] [Related]
46. Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.
Fujita N; Hatakeyama S; Okita K; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2021 Mar; 39(3):191.e9-191.e16. PubMed ID: 32713622
[TBL] [Abstract][Full Text] [Related]
47. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
[TBL] [Abstract][Full Text] [Related]
48. Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre.
Lobo N; Bree KK; Hensley PJ; Nogueras-Gonzalez GM; Abraham P; Navai N; Dinney CP; Kamat AM
BJU Int; 2022 Sep; 130(3):323-330. PubMed ID: 34847263
[TBL] [Abstract][Full Text] [Related]
49. Re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596.
Montorsi F; Rosiello G; Gandaglia G
Eur Urol Oncol; 2024 Apr; 7(2):300. PubMed ID: 37838554
[No Abstract] [Full Text] [Related]
50. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
51. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.
Gontero P; Sylvester R; Pisano F; Joniau S; Vander Eeckt K; Serretta V; Larré S; Di Stasi S; Van Rhijn B; Witjes AJ; Grotenhuis AJ; Kiemeney LA; Colombo R; Briganti A; Babjuk M; Malmström PU; Oderda M; Irani J; Malats N; Baniel J; Mano R; Cai T; Cha EK; Ardelt P; Varkarakis J; Bartoletti R; Spahn M; Johansson R; Frea B; Soukup V; Xylinas E; Dalbagni G; Karnes RJ; Shariat SF; Palou J
Eur Urol; 2015 Jan; 67(1):74-82. PubMed ID: 25043942
[TBL] [Abstract][Full Text] [Related]
52. A prospective descriptive 1-year study in France of all BCG therapy dispensations for non-muscle-invasive bladder cancer.
Neuzillet Y; Leon P; Seisen T; Allory Y; Audenet F; Loriot Y; Masson-Lecomte A; Mejean A; Pradère B; Roumiguié M; Traxer O; Xylinas E; Fournier G; Roupret M
BJU Int; 2023 May; 131(5):611-616. PubMed ID: 36462164
[TBL] [Abstract][Full Text] [Related]
53. Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
Gore JL; Wolff EM; Comstock BA; Follmer KM; Nash MG; Basu A; Chisolm S; MacLean DB; Lee JR; Lotan Y; Porten SP; Steinberg GD; Chang SS; Gilbert SM; Kessler LG; Smith AB;
BMC Cancer; 2023 Nov; 23(1):1127. PubMed ID: 37980511
[TBL] [Abstract][Full Text] [Related]
54. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
Hahn NM; O'Donnell MA; Efstathiou JA; Zahurak M; Rosner GL; Smith J; Kates MR; Bivalacqua TJ; Tran PT; Song DY; Baras AS; Matoso A; Choi W; Smith KN; Pardoll DM; Marchionni L; McGuire B; Grace Phelan M; Johnson BA; O'Neal T; McConkey DJ; Rose TL; Bjurlin M; Lim EA; Drake CG; McKiernan JM; Deutsch I; Anderson CB; Lamm DL; Geynisman DM; Plimack ER; Hallman MA; Horwitz EM; Al-Saleem E; Chen DYT; Greenberg RE; Kutikov A; Guo G; Masterson TA; Adra N; Kaimakliotis HZ
Eur Urol; 2023 Jun; 83(6):486-494. PubMed ID: 36717286
[TBL] [Abstract][Full Text] [Related]
55. Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era?
Tully KH; Cole AP; Krimphove MJ; Friedlander DF; Mossanen M; Herzog P; Noldus J; Sonpavde GP; Trinh QD
Urology; 2021 Jan; 147():199-204. PubMed ID: 32805294
[TBL] [Abstract][Full Text] [Related]
56. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
57. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
Kim HS; Seo HK
Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791
[TBL] [Abstract][Full Text] [Related]
58. Recurrence Rate and Cost Consequence of the Shortage of Bacillus Calmette-Guérin Connaught Strain for Bladder Cancer Patients.
Ourfali S; Ohannessian R; Fassi-Fehri H; Pages A; Badet L; Colombel M
Eur Urol Focus; 2021 Jan; 7(1):111-116. PubMed ID: 31005491
[TBL] [Abstract][Full Text] [Related]
59. Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy.
Iida K; Miyake M; Murakami K; Komiyama M; Okajima E; Sazuka T; Nishiyama N; Yasumoto H; Kimura T; Ito A; Shiga K; Yamagishi A; Kikuchi H; Sugimoto M; Taoka R; Kobayashi T; Kojima T; Kitamura H; Nishiyama H; Fujimoto K
Int J Clin Oncol; 2021 Nov; 26(11):2104-2112. PubMed ID: 34313904
[TBL] [Abstract][Full Text] [Related]
60. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S
Eur Urol Oncol; 2022 Apr; 5(2):195-202. PubMed ID: 35012889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]